Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Vertex Pharmaceuticals Incorporated (VRTX)

314.39   9.64 (3.16%) 03-24 16:00
Open: 305.38 Pre. Close: 304.75
High: 314.99 Low: 303
Volume: 2,376,513 Market Cap: 80,827(M)

Technical analysis

as of: 2023-03-24 4:31:15 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 367.9     One year: 429.71
Support: Support1: 295.59    Support2: 283.6
Resistance: Resistance1: 314.98    Resistance2: 367.9
Pivot: 295.7
Moving Average: MA(5): 303.72     MA(20): 294.28
MA(100): 302.57     MA(250): 289.33
MACD: MACD(12,26): 2.3     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 88.2     %D(3): 86.5
RSI: RSI(14): 66.7
52-week: High: 325.19  Low: 233
Average Vol(K): 3-Month: 1,272 (K)  10-Days: 1,175 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ VRTX ] has closed Bollinger Bands are 13.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 315.38 - 316.55 316.55 - 317.49
Low: 299.89 - 301.34 301.34 - 302.51
Close: 312.16 - 314.45 314.45 - 316.3

Company Description

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Headline News

Sat, 25 Mar 2023
Country Trust Bank Trims Stake in Vertex Pharmaceuticals ... - MarketBeat

Sat, 25 Mar 2023
Ronald Blue Trust Inc. Buys 1006 Shares of Vertex Pharmaceuticals ... - Defense World

Fri, 24 Mar 2023
VRTX: 4 Biotech Stocks You Don't Want to Miss out on in 2023 -

Fri, 24 Mar 2023
Guru Fundamental Report for VRTX - Nasdaq

Fri, 24 Mar 2023
Trading Update: Vertex Pharmaceuticals Incorporated (VRTX) Stock ... - The News Heater

Mon, 20 Mar 2023
Assenagon Asset Management S.A. Has $213.41 Million Holdings ... - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 257 (M)
Shares Float 256 (M)
% Held by Insiders 0.2 (%)
% Held by Institutions 96.3 (%)
Shares Short 2,680 (K)
Shares Short P.Month 3,150 (K)

Stock Financials

EPS 12.84
EPS Est Next Qtl 0.56
EPS Est This Year 1.62
EPS Est Next Year 2.89
Book Value (p.s.) 54.13
Profit Margin (%) 37.2
Operating Margin (%) 49
Return on Assets (ttm) 17.3
Return on Equity (ttm) 27.6
Qtrly Rev. Growth 11.1
Gross Profit (p.s.) 20.69
Sales Per Share 34.73
EBITDA (p.s.) 17.62
Qtrly Earnings Growth 5
Operating Cash Flow 4,130 (M)
Levered Free Cash Flow 3,310 (M)

Stock Valuations

PE Ratio 24.48
PEG Ratio 3.6
Price to Book value 5.8
Price to Sales 9.05
Price to Cash Flow 19.57

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.